STROME MARK E 4
4 · Zivo Bioscience, Inc. · Filed Oct 20, 2025
Insider Transaction Report
Form 4
STROME MARK E
10% Owner
Transactions
- Purchase
Common Stock
2025-10-13$12.34/sh+20,259$249,996→ 452,942 total(indirect: By entity) - Purchase
Common Stock Purchase Warrant
2025-10-13+2,025→ 43,071 total(indirect: By entity)Exercise: $12.34From: 2025-10-13Exp: 2030-10-12→ Common Stock (2,025 underlying)
Footnotes (3)
- [F1]The reported securities are owned directly by Strome Mezzanine Fund II, LP ("SMF II"), which were acquired pursuant to a Securities Purchase Agreement that SMF II entered into with the issuer.
- [F2]Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the "Reporting Persons") may be deemed to share voting and investment power for and to beneficially own the shares held by SMF II under Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act").
- [F3]Pursuant to Rule 16a-1(a)(4) of the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein.